Flotillin-2: A new potential predictor for prognosis of breast cancer
Sascha Pust, first author
Overexpression of ErbB2 occurs in up to 30% of human breast cancers. ErbB2 is not down-regulated by ligand-induced mechanisms as many other receptors. In a new study now published in Oncogene (journal impact factor 6.4), Sascha Pust (photo) from Kirsten Sandvig's group at the Institute for Cancer Research and coworkers show that flotillins stabilize ErbB2 at the plasma membrane. Moreover, microarray analysis of biopsies of 194 breast cancer patients indicated that flotillin-2 is a good prognostic marker for breast cancer. Depletion of flotillins leads to internalization and degradation of ErbB2, thereby inhibiting the ErbB2-triggered signaling.
This study was a collaboration between several groups, including three groups (Sandvig, Danielsen, Liestøl) from the Center for Cancer Biomedicine (CCB).
From major journals, first or last author from the Institute for Cancer Research
Bruland ØS, Larsen RH, Baum RP, Juzeniene A(2023) Editorial: Targeted alpha particle therapy in oncology Front Med (Lausanne), 10, 1165747 DOI 10.3389/fmed.2023.1165747, PubMed 36960341
Pettersen S, Øy GF, Egeland EV, Juell S, Engebråten O, Mælandsmo GM, Prasmickaite L(2023) Breast cancer patient-derived explant cultures recapitulate in vivo drug responses Front Oncol, 13, 1040665 DOI 10.3389/fonc.2023.1040665, PubMed 36910663
Chauhan SK, Casado RB, Landsverk OJB, Johannessen H, Phung D, Nilsen HR, Sætre F, Jahnsen J, Horneland R, Yaqub S, Aandahl EM, Lundin KEA, Bækkevold ES, Jahnsen FL(2023) The human small intestine contains two functionally distinct regulatory T-cell subsets J Allergy Clin Immunol(in press) DOI 10.1016/j.jaci.2023.02.030, PubMed 36893861
Arjona-Sanchez A, Martinez-López A, Moreno-Montilla MT, Mulsow J, Lozano-Lominchar P, Martínez-Torres B, Rau B, Canbay E, Sommariva A, Milione M, Deraco M, Sgarbura O, Torgunrud A, Kapenekian V, Carr NJ, Hoorens A, Delhorme JB, Wernert R, Goere D, Martin-Roman L, Cosyns S, Flatmark K, Davidson B, Khellaf L, Pereira-Perez Fet al.(2023) External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification Eur J Surg Oncol(in press) DOI 10.1016/j.ejso.2023.03.206, PubMed 36935222
Humbert M, Olofsson A, Wullimann D, Niessl J, Hodcroft EB, Cai C, Gao Y, Sohlberg E, Dyrdak R, Mikaeloff F, Neogi U, Albert J, Malmberg KJ, Lund-Johansen F, Aleman S, Björkhem-Bergman L, Jenmalm MC, Ljunggren HG, Buggert M, Karlsson AC(2023) Functional SARS-CoV-2 cross-reactive CD4+ T cells established in early childhood decline with age Proc Natl Acad Sci U S A, 120(12), e2220320120 DOI 10.1073/pnas.2220320120, PubMed 36917669
Halkola AS, Joki K, Mirtti T, Mäkelä MM, Aittokallio T, Laajala TD(2023) OSCAR: Optimal subset cardinality regression using the L0-pseudonorm with applications to prognostic modelling of prostate cancer PLoS Comput Biol, 19(3), e1010333 DOI 10.1371/journal.pcbi.1010333, PubMed 36897911